CG
ALXN

Colony Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Colony Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,720
Closed -$316K – 850
2021
Q2 		$316K Sell
1,720
-296
-15% -$50.8K 0.01% 621
2021
Q1 		$308K Sell
2,016
-1,051
-34% -$163K 0.01% 638
2020
Q4 		$479K Sell
3,067
-542
-15% -$69.6K 0.01% 514
2020
Q3 		$413K Sell
3,609
-46
-1% -$4.96K 0.01% 508
2020
Q2 		$410K Sell
3,655
-104
-3% -$11K 0.01% 492
2020
Q1 		$338K Buy
+3,759
New +$369K 0.01% 530
2019
Q3 		– Sell
-2,960
Closed -$388K – 734
2019
Q2 		$388K Sell
2,960
-815
-22% -$105K 0.01% 553
2019
Q1 		$510K Buy
+3,775
New +$469K 0.02% 392

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Colony Group's ALXN Position: Q3 2021 in Review

Colony Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,720 shares — an estimated $316K sold.

Colony Group first reported a position in ALXN in Q1 2019 and held it in 8 quarters. The position peaked at $510K in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Colony Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Colony Group sold 1,720 Alexion Pharmaceuticals shares in Q3 2021, an estimated $316K.
  • Colony Group first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 8 quarters.
  • Colony Group's Alexion Pharmaceuticals position peaked at $510K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Colony Group's 13F filing for Q3 2021, filed 17 Nov 2021.